In two prospective , double-blind , multicentre , phase @ studies ( UNCOVER-@ and UNCOVER-@ ) , eligible patients were aged @ years or older , had a confirmed diagnosis of chronic plaque psoriasis at least @ months before baseline ( randomisation ) , @ % or greater body-surface area involvement at both screening and baseline visits , at least a moderate clinical severity as measured by a static physician global assessment ( sPGA ) score of @ or more , and a psoriasis area and severity index ( PASI ) score of @ .